147 related articles for article (PubMed ID: 30552643)
1. Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T.
Duran-Lozano L; Montalban G; Bonache S; Moles-Fernández A; Tenés A; Castroviejo-Bermejo M; Carrasco E; López-Fernández A; Torres-Esquius S; Gadea N; Stjepanovic N; Balmaña J; Gutiérrez-Enríquez S; Diez O
Breast Cancer Res Treat; 2019 Apr; 174(2):543-550. PubMed ID: 30552643
[TBL] [Abstract][Full Text] [Related]
2. Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report.
Lopez-Perolio I; Leman R; Behar R; Lattimore V; Pearson JF; Castéra L; Martins A; Vaur D; Goardon N; Davy G; Garre P; García-Barberán V; Llovet P; Pérez-Segura P; Díaz-Rubio E; Caldés T; Hruska KS; Hsuan V; Wu S; Pesaran T; Karam R; Vallon-Christersson J; Borg A; ; Valenzuela-Palomo A; Velasco EA; Southey M; Vreeswijk MPG; Devilee P; Kvist A; Spurdle AB; Walker LC; Krieger S; de la Hoya M
J Med Genet; 2019 Jul; 56(7):453-460. PubMed ID: 30890586
[TBL] [Abstract][Full Text] [Related]
3. Splicing predictions, minigene analyses, and ACMG-AMP clinical classification of 42 germline PALB2 splice-site variants.
Valenzuela-Palomo A; Bueno-Martínez E; Sanoguera-Miralles L; Lorca V; Fraile-Bethencourt E; Esteban-Sánchez A; Gómez-Barrero S; Carvalho S; Allen J; García-Álvarez A; Pérez-Segura P; Dorling L; Easton DF; Devilee P; Vreeswijk MP; de la Hoya M; Velasco EA
J Pathol; 2022 Mar; 256(3):321-334. PubMed ID: 34846068
[TBL] [Abstract][Full Text] [Related]
4. A synonymous germline variant PALB2 c.18G>T (p.Gly6=) disrupts normal splicing in a family with pancreatic and breast cancers.
Yang C; Ceyhan-Birsoy O; Mandelker D; Jairam S; Catchings A; O'Reilly EM; Walsh MF; Zhang L
Breast Cancer Res Treat; 2019 Jan; 173(1):79-86. PubMed ID: 30255452
[TBL] [Abstract][Full Text] [Related]
5. Missense PALB2 germline variant disrupts nuclear localization of PALB2 in a patient with breast cancer.
Toh MR; Low CE; Chong ST; Chan SH; Ishak NDB; Courtney E; Kolinjivadi AM; Rodrigue A; Masson JY; Ngeow J
Fam Cancer; 2020 Apr; 19(2):123-131. PubMed ID: 32048105
[TBL] [Abstract][Full Text] [Related]
6. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family.
Yang C; Arnold AG; Trottier M; Sonoda Y; Abu-Rustum NR; Zivanovic O; Robson ME; Stadler ZK; Walsh MF; Hyman DM; Offit K; Zhang L
Breast Cancer Res Treat; 2016 Dec; 160(3):447-456. PubMed ID: 27757719
[TBL] [Abstract][Full Text] [Related]
8. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
[TBL] [Abstract][Full Text] [Related]
9. Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
Preobrazhenskaya EV; Shleykina AU; Gorustovich OA; Martianov AS; Bizin IV; Anisimova EI; Sokolova TN; Chuinyshena SA; Kuligina ES; Togo AV; Belyaev AM; Ivantsov AO; Sokolenko AP; Imyanitov EN
Int J Cancer; 2021 Jan; 148(1):203-210. PubMed ID: 32997802
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of PALB2-associated breast cancers.
Lee JEA; Li N; Rowley SM; Cheasley D; Zethoven M; McInerny S; Gorringe KL; James PA; Campbell IG
J Pathol; 2018 May; 245(1):53-60. PubMed ID: 29431189
[TBL] [Abstract][Full Text] [Related]
11. PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk.
Vagena A; Papamentzelopoulou M; Kalfakakou D; Kollia P; Papadimitriou C; Psyrri A; Apostolou P; Fountzilas G; Konstantopoulou I; Yannoukakos D; Fostira F
J Hum Genet; 2019 Aug; 64(8):767-773. PubMed ID: 31089269
[TBL] [Abstract][Full Text] [Related]
12. A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
Velázquez C; Esteban-Cardeñosa EM; Lastra E; Abella LE; de la Cruz V; Lobatón CD; Durán M; Infante M
Breast; 2019 Feb; 43():91-96. PubMed ID: 30521987
[TBL] [Abstract][Full Text] [Related]
13. Targeted massively parallel sequencing characterises the mutation spectrum of PALB2 in breast and ovarian cancer cases from Poland and Ukraine.
Myszka A; Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
Fam Cancer; 2018 Jul; 17(3):345-349. PubMed ID: 29052111
[TBL] [Abstract][Full Text] [Related]
14. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
15. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
[TBL] [Abstract][Full Text] [Related]
16. Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients.
Obermeier K; Sachsenweger J; Friedl TW; Pospiech H; Winqvist R; Wiesmüller L
Oncogene; 2016 Jul; 35(29):3796-806. PubMed ID: 26640152
[TBL] [Abstract][Full Text] [Related]
17. Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2.
Catucci I; Casadei S; Ding YC; Volorio S; Ficarazzi F; Falanga A; Marchetti M; Tondini C; Franchi M; Adamson A; Mandell J; Walsh T; Olopade OI; Manoukian S; Radice P; Ricker C; Weitzel J; King MC; Peterlongo P; Neuhausen SL
Breast Cancer Res Treat; 2016 Nov; 160(1):121-129. PubMed ID: 27624329
[TBL] [Abstract][Full Text] [Related]
18. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
[TBL] [Abstract][Full Text] [Related]
19. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
[TBL] [Abstract][Full Text] [Related]
20. Identification and Characterization of an Exonic Duplication in
Bouras A; Lafaye C; Leone M; Kherraf ZE; Martin-Denavit T; Fert-Ferrer S; Calender A; Boutry-Kryza N
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054852
[No Abstract] [Full Text] [Related]
[Next] [New Search]
